Overview

MEPO Study

Mepolizumab Long-term Access Program for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy)
Objective

Eosinophilic granulomatosis with polyangiitis (also known as Churg–Strauss syndrome) is a rare autoimmune condition that causes inflammation.  This study is not seeking to enroll additional patients.

Study Medication

Mepolizumab (Nucala™)

Study Coordinator(s)

Kim Glorieux, CRC: 425.635.6082, Kimberly.Glorieux@overlakehospital.org

Complete the online contact information form

Principal Investigator(s)

Amy Markezich, MD

Clinical Trial Categories

Pulmonary/Critical Care

View all hospital services

View all hospital services

Make a gift

Make a gift

Need urgent care?

Need urgent care?